United Therapeutics Corporation (UTHR) Financial Metrics
This dashboard provides comprehensive financial metrics and analysis to help evaluate United Therapeutics Corporation's investment potential. View key valuation ratios, profitability metrics, growth indicators, and historical trends to make informed investment decisions.
Financial Metrics Score
Valuation Metrics
Sector benchmarks: Industrials
P/E Ratio
16.17
Strong
WeakModerateStrong
P/B Ratio
3.04
Strong
WeakModerateStrong
Earnings Yield
6.18%
Strong
WeakModerateStrong
Profitability Health
2025Return on Equity
18.81%
Strong
WeakModerateStrong
Operating Margin
47.67%
Strong
WeakModerateStrong
Net Profit Margin
41.94%
Strong
WeakModerateStrong
Growth Indicators
2025Revenue Growth
10.61%
Strong
WeakModerateStrong
Net Income Growth
11.68%
Moderate
WeakModerateStrong
EPS Growth
13.96%
Moderate
WeakModerateStrong
Efficiency & Liquidity
2025Current Ratio
6.60
Strong
WeakModerateStrong
Quick Ratio
6.28
Strong
WeakModerateStrong
Asset Turnover
0.40x
Weak
WeakModerateStrong
Inventory Turnover
2.10x
Weak
WeakModerateStrong
Cash Flow & Resilience
Core fortress metrics for cash-rich balance sheets in high-inflation / tech-volatility regimes
Free Cash Flow Yield
4.82%
Strong
WeakModerateStrong
EV / Free Cash Flow
19.28x
Strong
WeakModerateStrong
Net Debt / EBITDA
-0.84x
Strong
WeakModerateStrong
Interest Burden (EBT / EBIT)
1.130
Strong
WeakModerateStrong
Return on Invested Capital
16.13%
Moderate
WeakModerateStrong
Cash Conversion Cycle
207.28 days
Weak
WeakModerateStrong
Fortress screener guardrails
2/4 passing
- FCF Yield > 3%
- Net Debt / EBITDA < 1.5x
- ROIC > 20%
- Cash Conversion Cycle < 0 days
Financial Statements
Want to see the complete financial picture? View detailed financial statements including income statements, balance sheets, and cash flow statements for UTHR.
View Financial Statements